Crescent Biopharma (CBIO) Cash from Financing Activities (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Cash from Financing Activities of $136000.0 for Q2 2026, down 99.91% year-over-year from $146.9 million in Q2 2025, and up 101.96% quarter-over-quarter from -$6.9 million in Q1 2026.
Crescent Biopharma (CBIO) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Cash from Financing Activities for 13 consecutive years, with $136000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 99.91% year-over-year to $136000.0; the TTM figure through Jun 2026 stood at $170.8 million (down 8.38% YoY), while the FY2025 annual figure was $323.0 million, up 5983301.26% from the prior year.
- Cash from Financing Activities rose to $136000.0 in Q2 2026 per CBIO's latest filing, from -$6.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $178.9 million in Q4 2025 and bottomed at -$6.9 million in Q1 2026.
- Historically, Cash from Financing Activities has averaged $29.7 million across 4 years, with a median of $20114.0 in 2023.
- On a YoY basis, Cash from Financing Activities climbed as much as 29372700.0% in 2025 and fell as far as 30438.91% in 2025.
- Crescent Biopharma's Cash from Financing Activities stood at $999.0 in 2023, then soared by 4107507.61% to $41.0 million in 2024, then soared by 335.87% to $178.9 million in 2025, then slumped by 99.92% to $136000.0 in 2026.
- Business Quant data shows CBIO's Cash from Financing Activities at $136000.0 in Q2 2026, -$6.9 million in Q1 2026, and $178.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | 136,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136,000.00 |
| Jun 30, 2026 | 136,000.00 |
| Mar 31, 2026 | -6.95 Mn |
| Mar 31, 2026 | -6.95 Mn |
| Dec 31, 2025 | 178.86 Mn |
| Dec 31, 2025 | 178.86 Mn |
| Sep 30, 2025 | -1.25 Mn |
| Sep 30, 2025 | -1.25 Mn |
| Jun 30, 2025 | 146.86 Mn |
| Jun 30, 2025 | 146.86 Mn |
| Mar 31, 2025 | -1.49 Mn |
| Mar 31, 2025 | -1.49 Mn |
| Dec 31, 2024 | 41.04 Mn |
| Dec 31, 2024 | 41.04 Mn |
| Jun 30, 2024 | 500.00 |
| Jun 30, 2024 | 500.00 |
| Mar 31, 2024 | 4,898.00 |
| Mar 31, 2024 | 4,898.00 |
| Dec 31, 2023 | 999.00 |
| Dec 31, 2023 | 999.00 |